Dr. Lal PathLabs Ltd has outlined a slate of leadership moves that underscore continuity at the top while widening operational leadership. The Board has re-appointed (Hony) Brig. Dr. Arvind Lal, Padma Shri, as Executive Chairman and Whole-Time Director for a five-year term beginning April 1, 2027, subject to member approval at the upcoming AGM. Alongside, Mr. Rajit Mehta is set to return as a Non-Executive Independent Director for a five-year period from July 27, 2026, also subject to shareholder consent. The changes come as the company maps its governance for the next phase, including the scheduling of its 32nd AGM on July 25, 2026, to formalize these appointments and other business matters.
In a move that signals a sharpening of scientific and laboratory leadership, Dr. Reena Nakra has been designated Senior Management Personnel as Chief Scientific Officer with effect from April 30, 2026. She is joined by Dr. Saloni Khera, designated as Senior Management Personnel and Chief Lab Management Officer, also effective April 30, 2026. These appointments place a premium on scientific leadership and operational excellence as the company navigates its expanding diagnostics footprint.
Beyond leadership roles, the board advanced growth strategies with a series of corporate actions. It approved the acquisition of Shahbazkers Diagnostic Centre Private Limited, aiming to bring it under Dr. Lal PathLabs as a wholly owned subsidiary, and sanctioned the incorporation of a wholly owned Dubai entity, Dr. Lal PathLabs FZCO, to support international forays. The company also advanced internal talent and alignment through the allotment of 82,750 equity shares under the Employee Stock Option Plan 2022, expanding the equity base to support long-term value creation. Together, the moves sketch a course of steady governance and strategic execution as Dr. Lal PathLabs positions itself for broader diagnostics leadership.